Capacity of proton beams in preserving normal liver tissue during proton beam therapy for hepatocellular carcinoma

被引:0
作者
Tsai, Yu-Lun [1 ]
Takei, Hideyuki [2 ]
Iizumi, Takashi [2 ,3 ]
Okumura, Toshiyuki [2 ,3 ]
Sekino, Yuta [2 ,3 ]
Numajiri, Haruko [2 ,3 ]
Ishikawa, Hitoshi [2 ,3 ]
Sakae, Takeji [2 ]
Sakurai, Hideyuki [2 ,3 ]
机构
[1] Cathay Gen Hosp, Dept Radiat Oncol, 280 Renai Rd Sec 4, Taipei, Taiwan
[2] Univ Tsukuba, Proton Med Res Ctr, Tsukuba, Ibaraki, Japan
[3] Univ Tsukuba, Fac Med, Dept Radiat Oncol, Tsukuba, Ibaraki, Japan
关键词
unirradiated liver volume; normal liver sparing; proton beam therapy; hepatocellular carcinoma; CHARGED-PARTICLE THERAPY; RADIATION-THERAPY; RISK-FACTORS; PHASE-II; RADIOTHERAPY; TOXICITY; OUTCOMES; TRIAL;
D O I
10.1093/jrr/rraa098
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Unirradiated liver volume (ULV) preservation rate is an important factor associated with radiation-induced liver disease (RILD) in patients with hepatocellular carcinoma (HCC) undergoing proton beam therapy (PBT). The purpose of this study is to identify the predictors for ULV preservation and quantify the capacity of proton beams in normal liver sparing during PBT. We reviewed planning data of 92 patients with single intrahepatic HCC tumors undergoing PBT. The potential clinical and planning factors that may affect ULV preservation were involved in multiple linear regression for ULV preservation rate. The significant factors were determined to be predictors and their influences were quantified. The median ULV preservation rate was 62.08%. All the assessed clinical factors showed significant effects on ULV preservation rate: clinical target volume (CTV), P < 0.001; portal vein tumor thrombosis (PVTT), P = 0.010; left lobe tumor, P = 0.010. In contrast, none of the planning factors demonstrated significance. The coefficients of significant factors in multiple linear regression were 60.85 for intercept, -0.02 for CTV, -9.01 for PVTT and 8.31 for left lobe tumors. The capacity of proton beams to spare normal liver tissue during PBT for HCC is mainly affected by clinical factors. The baseline of the ULV preservation rate is 60.85%, decreasing 0.02% with each milliliter of CTV increase and 9.01% for tumors with PVTT, and increasing 8.31% for tumors limited to the left lobe. Further clinical studies should be carried out to correlate our dosimetric findings with clinical outcomes.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 38 条
[1]   Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma [J].
Apisarnthanarax, Smith ;
Bowen, Stephen R. ;
Combs, Stephanie E. .
SEMINARS IN RADIATION ONCOLOGY, 2018, 28 (04) :309-320
[2]   Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis [J].
Bush, David A. ;
Smith, Jason C. ;
Slater, Jerry D. ;
Volk, Michael L. ;
Reeves, Mark E. ;
Cheng, Jason ;
Grove, Roger ;
de Vera, Michael E. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (01) :477-482
[3]   The Safety and Efficacy of High-Dose Proton Beam Radiotherapy for Hepatocellular Carcinoma: A Phase 2 Prospective Trial [J].
Bush, David A. ;
Kayali, Zeid ;
Grove, Roger ;
Slater, Jerry D. .
CANCER, 2011, 117 (13) :3053-3059
[4]   Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma [J].
Chadha, Awalpreet S. ;
Gunther, Jillian R. ;
Hsieh, Cheng-En ;
Aliru, Maureen ;
Mahadevan, Lakshmi S. ;
Venkatesulu, Bhanu P. ;
Crane, Christopher H. ;
Das, Prajnan ;
Herman, Joseph M. ;
Koay, Eugene J. ;
Taniguchi, Cullen ;
Holliday, Emma B. ;
Minsky, Bruce D. ;
Suh, Yelin ;
Park, Peter ;
Sawakuchi, Gabriel ;
Beddar, Sam ;
Odisio, Bruno C. ;
Gupta, Sanjay ;
Loyer, Evelyne ;
Kaur, Harmeet ;
Raghav, Kanwal ;
Javle, Milind M. ;
Kaseb, Ahmed O. ;
Krishnan, Sunil .
RADIOTHERAPY AND ONCOLOGY, 2019, 133 :54-61
[5]   Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints [J].
Chapman, Tobias R. ;
Bowen, Stephen R. ;
Schaub, Stephanie K. ;
Yeung, Rosanna H. ;
Kwan, Sharon W. ;
Park, James O. ;
Yu, Lei ;
Harris, William P. ;
Johnson, Guy E. ;
Liou, Iris W. ;
Nyflot, Matthew J. ;
Apisarnthanarax, Smith .
PRACTICAL RADIATION ONCOLOGY, 2018, 8 (03) :157-166
[6]   Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients [J].
Chiba, T ;
Tokuuye, K ;
Matsuzaki, Y ;
Sugahara, S ;
Chuganji, Y ;
Kagei, K ;
Shoda, J ;
Hata, M ;
Abei, M ;
Igaki, H ;
Tanaka, N ;
Akine, Y .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3799-3805
[7]   Assessment of out-of-field absorbed dose and equivalent dose in proton fields [J].
Clasie, Ben ;
Wroe, Andrew ;
Kooy, Hanne ;
Depauw, Nicolas ;
Flanz, Jay ;
Paganetti, Harald ;
Rosenfeld, Anatoly .
MEDICAL PHYSICS, 2010, 37 (01) :311-321
[8]  
Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8
[9]   A PROSPECTIVE STUDY OF HYPOFRACTIONATED PROTON BEAM THERAPY FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA [J].
Fukumitsu, Nobuyoshi ;
Sugahara, Shinji ;
Nakayama, Hidetsugu ;
Fukuda, Kuniaki ;
Mizumoto, Masashi ;
Abei, Masato ;
Shoda, Junichi ;
Thono, Eriko ;
Tsuboi, Koji ;
Tokuuye, Koichi .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (03) :831-836
[10]   Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation [J].
Hasan, Shaakir ;
Abel, Stephen ;
Verma, Vivek ;
Webster, Patrick ;
Arscott, W. Tristam ;
Wegner, Rodney E. ;
Kirichenko, Alexander ;
Simone, Charles B., II .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (05) :999-1009